Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Dow
Novartis
Boehringer Ingelheim
Mallinckrodt
Medtronic
UBS
Teva
US Department of Justice
Queensland Health

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,641,841

« Back to Dashboard

Which drugs does patent 6,641,841 protect, and when does it expire?

Patent 6,641,841 protects STARLIX and is included in one NDA.

This patent has twenty-one patent family members in thirteen countries.
Summary for Patent: 6,641,841
Title: Tablet composition
Abstract:A tablet composition containing N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and low substituted hydroxypropylcellulose is disclosed. This tablet composition is rapidly disintegrated in the stomach after the administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.
Inventor(s): Yabuki; Akira (Kawasaki, JP), Kaida; Masato (Kawasaki, JP), Ando; Takahiko (Kawasaki, JP), Ninomiya; Nobutaka (Kawasaki, JP), Ozaki; Masanao (Kawasaki, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP)
Application Number:09/920,830
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 6,641,841

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis STARLIX nateglinide TABLET;ORAL 021204-001 Dec 22, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe Y USE AS A BLOOD GLUCOSE-LOWERING AGENT ➤ Subscribe
Novartis STARLIX nateglinide TABLET;ORAL 021204-002 Dec 22, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y USE AS A BLOOD GLUCOSE-LOWERING AGENT ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,641,841

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-318541Nov 15, 1996

Non-Orange Book US Patents Family Members for Patent 6,641,841

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,323 Tablet composition ➤ Subscribe
6,296,872 Tablet composition of N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine ➤ Subscribe
6,844,008 Tablet composition ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,641,841

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0965339 ➤ Subscribe
European Patent Office 1586314 ➤ Subscribe
European Patent Office 2277517 ➤ Subscribe
Spain 2257772 ➤ Subscribe
Spain 2364145 ➤ Subscribe
Japan H10194969 ➤ Subscribe
Portugal 1586314 ➤ Subscribe
Japan 4171091 ➤ Subscribe
South Korea 20000053312 ➤ Subscribe
South Korea 100343062 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Teva
Citi
Boehringer Ingelheim
Julphar
Harvard Business School
Chubb
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot